NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation
| Autor: | Boglarka Mikudina, Melinda Goodall, Amanda I Adler |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Lymphocytic leukaemia
17p deletion business.industry Tp53 mutation medicine.disease Nice guidance 03 medical and health sciences Leukemia chemistry.chemical_compound 0302 clinical medicine Oncology chemistry 030220 oncology & carcinogenesis Ibrutinib Mutation (genetic algorithm) Cancer research medicine 030212 general & internal medicine Previously treated business |
| Zdroj: | The Lancet Oncology. 18:289-290 |
| ISSN: | 1470-2045 |
| DOI: | 10.1016/s1470-2045(17)30062-1 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|